Literature DB >> 2232890

Chronic myelomonocytic leukemia.

A M Storniolo1, W C Moloney, D S Rosenthal, C Cox, J M Bennett.   

Abstract

Thirty adult patients with CMML were evaluated to determine prognostic factors that might have an impact on conversion to acute leukemia and survival. Neither leukocyte count nor monocyte count correlated with survival. The median survival for all 30 cases was 41 months. Patients with less than 5% marrow blasts had a median survival of 60 months but those with 5-20% blasts had only a 9-month median survival.

Entities:  

Mesh:

Year:  1990        PMID: 2232890

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  11 in total

1.  [Clinical course, morphology and prognosis of chronic myelomonocytic leukemia].

Authors:  U Germing; C Strupp; G Meckenstock; A Giagounidis; H Minning; C Aul
Journal:  Med Klin (Munich)       Date:  1999-09-15

2.  Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia.

Authors:  Dorothée Selimoglu-Buet; Orianne Wagner-Ballon; Véronique Saada; Valérie Bardet; Raphaël Itzykson; Laura Bencheikh; Margot Morabito; Elisabeth Met; Camille Debord; Emmanuel Benayoun; Anne-Marie Nloga; Pierre Fenaux; Thorsten Braun; Christophe Willekens; Bruno Quesnel; Lionel Adès; Michaela Fontenay; Philippe Rameau; Nathalie Droin; Serge Koscielny; Eric Solary
Journal:  Blood       Date:  2015-04-07       Impact factor: 22.113

3.  Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories.

Authors:  Sanam Loghavi; Dawen Sui; Peng Wei; Guillermo Garcia-Manero; Sherry Pierce; Mark J Routbort; Elias J Jabbour; Naveen Pemmaraju; Rashmi Kanagal-Shamanna; H Deniz Gur; Shimin Hu; Zhuang Zuo; L Jeffrey Medeiros; Hagop M Kantarjian; Joseph D Khoury
Journal:  Blood Adv       Date:  2018-08-14

4.  Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.

Authors:  Ana Alfonso; Guillermo Montalban-Bravo; Koichi Takahashi; Elias J Jabbour; Tapan Kadia; Farhad Ravandi; Jorge Cortes; Zeev Estrov; Gautam Borthakur; Naveen Pemmaraju; Marina Konopleva; Carlos Bueso-Ramos; Sherry Pierce; Hagop Kantarjian; Guillermo Garcia-Manero
Journal:  Am J Hematol       Date:  2017-05-26       Impact factor: 10.047

5.  Significance of abnormal blood coagulation in patients with chronic myelomonocytic leukemia.

Authors:  Christoph Weinfurtner; Klaus Geissler
Journal:  Wien Med Wochenschr       Date:  2022-10-07

6.  Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemia.

Authors:  Gregor Eisenwort; Irina Sadovnik; Alexandra Keller; Daniel Ivanov; Barbara Peter; Daniela Berger; Gabriele Stefanzl; Karin Bauer; Katharina Slavnitsch; Georg Greiner; Karoline V Gleixner; Wolfgang R Sperr; Michael Willmann; Heinz Sill; Peter Bettelheim; Klaus Geissler; Michael Deininger; Thomas Rülicke; Peter Valent
Journal:  Leukemia       Date:  2021-03-30       Impact factor: 12.883

Review 7.  Chronic myelomonocytic leukemia.

Authors:  John M Bennett
Journal:  Curr Treat Options Oncol       Date:  2002-06

Review 8.  Models of Prognostication in Chronic Myelomonocytic Leukemia.

Authors:  Francesco Onida
Journal:  Curr Hematol Malig Rep       Date:  2017-12       Impact factor: 3.952

9.  CD 34 immunotyping of blasts in myelodysplasia.

Authors:  J Oertel; B Oertel; J Beyer; D Huhn
Journal:  Ann Hematol       Date:  1994-02       Impact factor: 3.673

Review 10.  Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions.

Authors:  Peter Valent; Attilio Orazi; Michael R Savona; Mrinal M Patnaik; Francesco Onida; Arjan A van de Loosdrecht; Detlef Haase; Torsten Haferlach; Chiara Elena; Lisa Pleyer; Wolfgang Kern; Tea Pemovska; Gregory I Vladimer; Julie Schanz; Alexandra Keller; Michael Lübbert; Thomas Lion; Karl Sotlar; Andreas Reiter; Theo De Witte; Michael Pfeilstöcker; Klaus Geissler; Eric Padron; Michael Deininger; Alberto Orfao; Hans-Peter Horny; Peter L Greenberg; Daniel A Arber; Luca Malcovati; John M Bennett
Journal:  Haematologica       Date:  2019-05-02       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.